<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="Activity\PMC7594867\results\search\disease\results.xml">
  <result pre="hits were synthesised and evaluated for their cytotoxicity against three" exact="cancer" post="(MCF-7, A2780, and HT29) and one normal (MRC-5) cell"/>
  <result pre="highlighted the importance of CDK-2 as a potential target in" exact="cancer" post="chemotherapy. Several small molecule inhibitors of CDK-2 have proved"/>
  <result pre="the new compounds were evaluated for their cytotoxicity against three" exact="cancer" post="(MCF-7, A2780, and HT29) cell lines. Selection of these"/>
  <result pre="IC50 values (the concentration required to inhibit the growth of" exact="cancer" post="cells by 50% compared to the untreated control), Table"/>
  <result pre="the new compounds to inhibit the growth of the selected" exact="cancer" post="cell lines with IC50 values in the range of"/>
  <result pre="4-methoxyphenyl-urea derivatives 17aâ€&quot;c showed potent cytotoxic activity against the three" exact="cancer" post="cell lines with IC50 values in the range of"/>
  <result pre="18aâ€&quot;c showed moderate to potent cytotoxic activities against the three" exact="cancer" post="cell lines (IC50 = 0.19â€&quot;10.76â€‰Î¼M). Among these derivatives compound"/>
  <result pre="(SI) = IC50 value against normal MRC-5 cells/IC50 value against" exact="cancer" post="cell line. The results revealed IC50 values in the"/>
  <result pre="normal MRC-5 cells by its IC50 value against the corresponding" exact="cancer" post="cell line, Table 3. Among the new compounds, the"/>
  <result pre="derivatives 17aâ€&quot;c exhibited higher selectivity (SI = 5.23â€&quot;14.76) towards the" exact="ovarian cancer" post="cell line (A2780) compared to their 4-fluorophenyl analogues 18aâ€&quot;c."/>
  <result pre="17aâ€&quot;c exhibited higher selectivity (SI = 5.23â€&quot;14.76) towards the ovarian" exact="cancer" post="cell line (A2780) compared to their 4-fluorophenyl analogues 18aâ€&quot;c."/>
  <result pre="(IC50 = 0.35â€&quot;0.85â€‰Î¼M) and was the most selective towards three" exact="cancer" post="cell lines. Figure 6. SAR of cytotoxicity and selectivity"/>
  <result pre="16a was associated with decrease in selectivity towards the three" exact="cancer" post="cell lines, Figure 6. Replacement of the hexyl group"/>
  <result pre="compound 18a with sharp decrease in cytotoxicity against the three" exact="cancer" post="cell lines. On the other hand, substitution on the"/>
  <result pre="which was more active as cytotoxic agent against the three" exact="cancer" post="cell lines. Although cytotoxicity of compound 19a was decreased"/>
  <result pre="4-CH3/Cl groups resulted in weaker cytotoxic activities against the three" exact="cancer" post="cell lines, Figure 6. 3.2.2. Annexin V-FITC/PI apoptosis assay"/>
  <result pre="activity Targeting CDKs is one of the promising strategies in" exact="cancer" post="chemotherapy6. The success of this strategy was confirmed by"/>
  <result pre="were synthesised and evaluated for their cytotoxic activities against three" exact="cancer" post="(MCF-7, A2780, and HT29) cell lines. The results revealed"/>
  <result pre="cell lines. The results revealed cytotoxic activities against the three" exact="cancer" post="cell lines with IC50 values in the range of"/>
  <result pre="ahead. Nat Rev Drug Discov2018;17:353â€&quot;77.29545548 2BhullarKS, LagaronNO, McGowanEM, et al.Kinase-targeted" exact="cancer" post="therapies: progress, challenges and future directions. Mol Cancer2018;17:48.29455673 3WuP,"/>
  <result pre="Probl Cancer2013;37:110â€&quot;44.23972982 6TadesseS, CaldonEC, TilleyW, WangS.Cyclin-dependent kinase 2 inhibitors in" exact="cancer" post="therapy: an update. J Med Chem2019;62:4233â€&quot;51.30543440 7TsaiLH, LeesE, FahaB,"/>
  <result pre="cells. Oncogene1993;8:1593â€&quot;602.8502482 8KeyomarsiK, PardeeAB.Redundant cyclin overexpression and gene amplification in" exact="breast cancer" post="cells. Proc Natl Acad Sci U S A1993;90:1112â€&quot;6.8430082 9YangL,"/>
  <result pre="Oncogene1993;8:1593â€&quot;602.8502482 8KeyomarsiK, PardeeAB.Redundant cyclin overexpression and gene amplification in breast" exact="cancer" post="cells. Proc Natl Acad Sci U S A1993;90:1112â€&quot;6.8430082 9YangL,"/>
  <result pre="expression in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in" exact="colon cancer" post="cells. Int J Oncol1998;13:233â€&quot;9.9664116 11WangJ, YangT, XuG, et al.Cyclin-dependent"/>
  <result pre="in colon carcinogenesis and effects of cdk2/cdc2 inhibitor in colon" exact="cancer" post="cells. Int J Oncol1998;13:233â€&quot;9.9664116 11WangJ, YangT, XuG, et al.Cyclin-dependent"/>
  <result pre="al.Identification of CDK2 as a novel target in treatment of" exact="prostate cancer." post="Future Oncol2018;14:709â€&quot;18.29323532 14LinZP, ZhuYL, RatnerES.Targeting cyclin-dependent kinases for treatment"/>
  <result pre="al.The CDK inhibitor AT7519M in patients with relapsed or refractory" exact="chronic lymphocytic leukemia" post="(CLL) and mantle cell lymphoma. A Phase II study"/>
  <result pre="inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic" exact="leukemia" post="(CLL) and mantle cell lymphoma. A Phase II study"/>
  <result pre="patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and" exact="mantle cell lymphoma." post="A Phase II study of the Canadian Cancer Trials"/>
  <result pre="membranacea essential oil and its major constituent 1,8-cineole against A2780" exact="ovarian cancer" post="cells. Molecules2020;25:1582. 45WangY, ChenY, ChengX, et al.Design, synthesis and"/>
  <result pre="essential oil and its major constituent 1,8-cineole against A2780 ovarian" exact="cancer" post="cells. Molecules2020;25:1582. 45WangY, ChenY, ChengX, et al.Design, synthesis and"/>
  <result pre="CDK2 inhibitors that induce apoptosis and cell cycle arrest in" exact="breast cancer" post="cells. Bioorg Med Chem2018;26:3491â€&quot;501.29853338 46MorrisGM, HueyR, LindstromW, et al.AutoDock4"/>
  <result pre="inhibitors that induce apoptosis and cell cycle arrest in breast" exact="cancer" post="cells. Bioorg Med Chem2018;26:3491â€&quot;501.29853338 46MorrisGM, HueyR, LindstromW, et al.AutoDock4"/>
  <result pre="TurnerNC, KnudsenES.The history and future of targeting cyclin-dependent kinases in" exact="cancer" post="therapy. Nat Rev Drug Discov2015;14:130â€&quot;46.25633797 58WangJ, UrbÃ¡nL.The impact of"/>
 </snippets>
</snippetsTree>
